Cardiovascular Biologics Market Expected to Reach USD 4.23 Billion by 2033 Amid Advances in RNA and Biologic Therapies | DataM Intelligence [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
approximately USD 2.20 billion in 2024 and is projected to grow to USD 4.23 billion by 2033 , representing a CAGR of 7.5% over the forecast period 2025-2033 DataM Intelligence 4Market Research LLP - Logo (PRNewsfoto/DataM Intelligence) This growth is driven by the increasing development of biologic and gene-based therapies targeting cardiovascular disease (CVD) pathways, including monoclonal antibodies (mAbs), siRNA-based therapeutics, recombinant proteins and other biologic platforms. Growth Drivers: Innovation Meets Unmet Clinical Need Rising global burden: Cardiovascular diseases account for 18 million deaths annually , representing nearly 32% of all global fatalities (WHO, 2024). Therapy adoption rate: Biologic penetration in cardiovascular therapeutics increased from 3% in 2019 to 9% in 2024 , projected to exceed 20% by 2030 R&D investment: Annual cardiovascular biologics R&D spending surpassed USD 2.5 billion in 2024 , a 40% increase since 2020, led by mRNA and siRNA
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (NASDAQ:AMGN) was upgraded by analysts at Erste Group Bank AG from a "hold" rating to a "buy" rating.MarketBeat
- Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Amgen (NASDAQ:AMGN) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.MarketBeat
- Accord Healthcare Announces Launch of Denosumab? - Second Biosimilar in Bone Health [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Accord Healthcare Announces Launch of Denosumab? - Second Biosimilar in Bone Health [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website